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Background: Angiotensin II (Ang II) and transforming growth factor β (TGFβ) are closely involved in the pathogenesis
of diabetic complications. We aimed to determine whether an aberrant thrombospondin 1 (TSP1)–mediated
TGFβ1/Smads signaling pathway specifically affects vascular fibrosis in diabetic rats and whether valsartan, an
Ang II subtype 1 receptor blocker, has an anti-fibrotic effect.
Methods: Age-matched male Wistar rats were randomly divided into 3 groups: control (n = 8), diabetes (n = 16)
and valsartan (30 mg/kg/day) (n = 16). Type 2 diabetes mellitus (T2DM) was induced by a high-calorie diet and
streptozotocin injection. Morphological and biomechanical properties of the thoracic aorta were assessed by
echocardiography and cardiac catheterization. Masson staining was used for histological evaluation of extracellular
matrix (ECM). The expression of components in the TSP1–mediated TGFβ1/Smads signaling pathway was analyzed by
immunohistochemistry and real-time quantitative reverse transcription polymerase chain reaction.
Results: As compared with controls, diabetic aortas showed reduced distensibility and compliance, with excess ECM
deposition. Components in the TSP1-mediated TGFβ1/Smads signaling pathway, including TSP1, TGFβ1, TGFβ type II
receptor (TβRII), Smad2 and Smad3, were accumulated in vascular smooth muscle cytoplasm of diabetic aortas and
their protein and mRNA levels were upregulated. All these abnormalities were attenuated by valsartan.
Conclusions: TSP1-mediated TGFβ1/Smads pathway activation plays an important role in marcovascular remodeling in
T2DM in rat. Valsartan can block the pathway and ameliorate vascular fibrosis.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1053842818141195
Keywords: Diabetes, Macrovascular remodeling, Thrombospondin 1, Transforming growth factor β1, Smads, valsartanBackground
Diabetes is a serious health problem worldwide, and the
total number of diabetic patients is projected to increase
from 171 million in 2000 to 366 million in 2030 [1]. A
growing body of evidence supports diabetes associated
with various cardiovascular complications, including
macro- and microangiopathies. Hyperglycemia-induced* Correspondence: zhongming2@medmail.com.cn
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creativecommons.org/publicdomain/zero/1.0/unfavorable remodeling has been reported in the thor-
acic aorta [2], coronary artery [3], renal vasculature [4]
and intestinal arterioles [5] of diabetic animal models.
Vascular remodeling, characterized by alterations in the
composition and assembly of extracellular matrix (ECM),
is involved in accelerated atherosclerosis.
Transforming growth factor β (TGFβ) plays a critical
role in modulating the synthesis and degradation of
ECM. It is secreted as a latent complex (L-TGFβ), which
contains a latency-associated peptide (LAP) and a C-
terminal bioactive region. On stimulation with multiple
factors by enzymatic cleavage of or physical interaction
with LAP, an active form of TGFβ (A-TGFβ) is releasedle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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target genes by binding to specific receptors (TβRs) and
subsequent phosphorylation of Smads [6,7]. Experimental
and clinical studies indicate that hyperglycemia stimulates
the production of TGFβ1, thrombospondin 1 (TSP1), and
angiotensin II (Ang II) in the diabetic condition [8,9].
TSP1 is a matricellular protein involved in ECM forma-
tion. It can activate TGFβ1 endogenously by binding to the
LAP and mature domain of TGFβ1 [10]. TSP1-mediated
TGFβ1/Smads signaling contributes to target-organ dam-
age in animals with diabetic nephropathy [11] and dia-
betic cardiomyopathy [12]. In addition, glucose or Ang
II alone or in combination upregulates TSP1 and ele-
vates TGFβ1 activity. These effects can be antagonized
by Ang II subtype 1 receptor blockers (ARBs), which
suggests stimulation of the renin–angiotensin system
(RAS) in the development and progression of renal and
cardiac fibrosis [13].
However, we lack information on macrovascular lesions
provoked by TSP1 in diabetes. Therefore, we hypothesized
that hyperglycemia promotes the accumulation of ECM in
the thoracic aorta through an Ang II-TSP1-TGFβ1/Smads
pathway and examined whether valsartan, an ARB widely




Age-matched male Wistar rats (200–240 g, 48–50 days)
obtained from Shandong University Laboratories Animal
Center (Jinan, China) were randomly divided into 3 groups:
control (n = 8), diabetic (n = 16) and valsartan (n = 16). Ani-
mals in the control group were fed normal chow (8% fat,
16% protein, 50% carbohydrate, and 22% other ingredients;
total calories 14 kJ/g) and the other 2 groups a high-calorie
diet (25% fat, 14% protein, 51% carbohydrate, and 10%
other ingredients; total calories 20 kJ/g). Four weeks later,
venous blood was sampled for measuring fasting plasma
glucose (FPG) and fasting insulin (Ins). After another
week, streptozotocin (STZ; Sigma, St. Louis, MO; 30 mg/kg,
dissolved in ice-cold 10 mM citrate buffer, pH 4.4) was ad-
ministered intraperitoneally to diabetic and valsartan
groups, and an equivalent volume of citrate buffer was ad-
ministered to the control group. One week after STZ in-
jection, blood samples were collected from the tail vein
for measuring FPG and Ins. Diabetes was defined as FPG
≥11.1 mmol/L and insulin sensitivity index [ISI =
Ln(FPG× Ins)-1] lower than that of controls. Rats in the
valsartan group were given valsartan (30 mg/kg) via intra-
gastric administration every day, and those in control and
diabetic groups received the same dose of normal saline.
Animals were maintained in individual air-filtered meta-
bolic cages with free access to water for 16 weeks. FPG
and Ins were measured at the end of the experiment, withISI calculated. This study conformed to the Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–23,
revised 1996). The protocol was granted by the institu-
tional medical ethics review board.
Echocardiography and cardiac catheterization
At the end of the experiment, rats were anesthetized with
chloral hydrate (300 mg/kg, intraperitoneally). Transtho-
racic echocardiography was performed with use of a
SONOS 7500 (Hewlett-Packard, Andover, MA, USA) with
a 12 MHz transducer. The inner diameter of the thoracic
aorta was measured in systolic and diastolic phases (Ds,
Dd) in a long axis view. Subsequently, a catheter (PE-50)
was introduced into the aortic arch via the right carotid
artery and connected to a pressure transducer for measur-
ing aortic systolic blood pressure (SBP) and diastolic blood
pressure (DBP). Aortic distensibility and compliance were
determined by calculating distensibility coefficient (DC)
and compliance coefficient (CC), respectively, by the fol-
lowing formulas [14,15]:
DC ¼ ΔA=Að Þ=ΔP ¼ 2 ΔDxDdþ ΔD2 = ΔPxDd2 :
CC ¼ ΔV=ΔLð Þ=ΔP ¼ A=P ¼ π 2ΔDxDdþ ΔD2 =4ΔP:
ΔP ¼ SBP‐DBP: ΔD ¼ Dd‐Ds:
Tissue preparation
Animals were killed by an overdose of chloral hydrate.
The thoracic aorta was excised immediately and dropped
into an ice-cold NaCl 0.9% buffer. Tissues (5 × 5 ×
5 mm3 aortic wall) for immunohistochemistry were fixed
in 10% formaldehyde and paraffin embedded. The
remaining aorta was cut into small tissue blocks and
stored in foil packets at −80 °C for the following
experiments.
Histological evaluation of extracellular matrix (ECM)
Sections 4 μm thick were deparaffined and stained with
Masson’s trichrome for ECM. Ten successive microscopy
fields were examined with use of the JD801 Imaging
Analysis System (Jiangsu JEDA Science-Technology
Development Co.). The content of aortic ECM was
semi-quantified as the proportion of area occupied by
Masson’s staining to total area.
Immunohistochemistry
Immunohistochemistry involved a microwave-based antigen-
retrieval technique. After the removal of paraffin, endogen-
ous peroxidase was neutralized with H2O2 (0.3% vol/vol)
for 10 min. Sections were placed in phosphate-buffered
saline (PBS) for 15 min and protein-blocking solution
(Immunotech, Cedex, France) for another 30 min,
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with secondary antibodies for 1 hour at room temperature,
and finally horseradish peroxidase–conjugated streptavidin
(Dako; diluted 1:500) for visualization. The expression
of TSP1, L-TGFβ1, A-TGFβ1, TβRII and p-Smad2/3
was evaluated by use of the JD801 imaging analysis sys-
tem. The percentage positive staining in the vascular
wall was semi-quantified under a microscope.Real time quantitative reverse transcription polymerase
chain reaction (RT-PCR)
Total RNA was extracted from aortic tissues by use of
Trizol reagent and treated with DNase to avoid DNA
contamination. After quantification at the extinction co-
efficient of 260 nm, total RNA was reverse-transcribed
into cDNA following the manufacturer’s instructions
(TakaRa, Dalian, China), and real-time PCR involved an
ABI Prism 7000 sequence detector system with the
SYBR Green Reaction Kit. Primers are in Table 1. Amp-
lification products were analyzed by a melting curve,
which confirmed a single PCR product in all reactions.
The expression of specific genes was normalized to that
of β-actin as the housekeeping gene.Statistical analysis
Data are expressed as mean ± SD. Statistical analysis
involved use of SPSS 11.0 (SPSS, Chicago, IL), with
unpaired Student t test for comparisons between 2
groups and ANOVA followed by Scheffe’s procedure
for 3 groups. P < 0.05 was considered statistically




TSP 1 Forward: 5’-GGAAGAGCATCACGCTGTTTG-3’
Reverse: 5’-GCGCTCTCCATCTTGTCACA-3’
TGFβ1 Forward: 5’ TTGCCCTCT ACAACCAACACAA-3’
Reverse: 5’-GGCTTGCGACCCACGTAGTA- 3’
TβRII Forward: 5’ TCA CCT ACC ACG GCT TCA CTC T 3’
Reverse: 5’ CGC CCT TTT CTT TTC CTT CA 3’
Smad2 Forward: 5’- TGT GCA GAG CCC CAA CTG TA -3’
Reverse: 5’- TGG TGG GAT TTT GCA CAC TGT -3’
Smad3 Forward: 5’- CAA CCC CTC AGG TTC TCTGAA G -3’
Reverse: 5’- GCA GTC CAC AGA CCA TGT CAA -3’
β-actin Forward: 5’- TTC AAC ACC CCA GCC ATG T -3’
Reverse: 5’- GTG GTA CGA CCA GAG GCA TAC A -3’
Abbreviations: TGFβ1 transforming growth factor β1, TβRII TGF β type II
receptor, TSP1 thrombospondin 1.Results
Characteristics of experimental animals
During the experiment, 3 rats died in the diabetic group
and 2 in the valsartan group. These deaths were attributable
to ketoacidosis, infections or other complications induced
by hyperglycemia. The FPG and ISI of 3 rats treated with
a high-calorie diet and STZ did not meet the definition of
diabetes. Finally, 8 rats were included in control group, 11
in diabetic group, and 13 in valsartan group. Biochemical
characteristics, including FPG, Ins, and ISI, were similar
between diabetic and valsartan groups across the experi-
ment. However, as compared with controls, diabetic and
valsartan groups showed significantly elevated Ins before
STZ injection (P < 0.05), higher FPG one week after STZ
injection (P < 0.01), and consistently lower ISI (P < 0.01;
Figure 1).
Morphological and biomechanical properties of thoracic
aortas
Compared with controls, diabetic aortas were enlarged
in systolic and diastolic diameters (P < 0.01) but reduced
in distensibility and compliance (P < 0.05), which sug-
gested macrovascular remodeling (Table 2). As compared
with diabetic aortas, valsartan aortas showed increased dis-
tensibility and compliance (P < 0.05) and reduced systolic
and diastolic diameters, but not significantly, which indi-
cated some improvement in remodeling with valsartan.
Fibrosis in thoracic aortas
Masson staining demonstrated well-arranged aortic fibrous
tissue in control rats (Figure 2A). The diabetic group
showed disarranged fibers (Figure 2B). However, histo-
logical manifestations were attenuated in the valsartan
group as compared with the diabetic group (Figure 2C).
The content of ECM in the thoracic aorta was higher in
diabetic rats than controls (25.73 ± 4.85% vs. 17.12 ± 4.65%;
P < 0.01). As compared with diabetic aortas, valsartan
aortas showed reduced ECM content (20.81 ± 5.41% vs.
25.73 ± 4.85%, P < 0.05).
Protein content of components in the TSP1-mediated TGF
β1/Smads pathway
On immunohistochemistry (Figure 3), staining for TSP1,
L-TGFβ1 and A-TGFβ1, TβRII, and phosphorylated
Smad 2/3 (p-Smad2/3) in vascular smooth muscle cyto-
plasm was high in diabetic aortas, moderate in valsartan
aortas and low in controls.
Transcription of components in TSP1-mediated TGF
β1/Smads pathway
Real-time quantitative RT-PCR (Figure 4) demonstrated
greatly upregulated mRNA levels of TSP1, TGFβ1, TβRII,
Smad2 and Smad3 in diabetic than control aortas, with
Figure 1 Biochemical characteristics of thoracic aortas.
Measurements of fasting plasma glucose (A) and fasting insulin (B)
before STZ injection (4 week), 1 week after STZ injection (6 week)
and the end of the experiment (22 week), with ISI (C) calculated. *P
< 0.05 and **P < 0.01, vs controls. Abbreviations: ISI, insulin sensitivity
index; STZ, streptozotocin.
Table 2 Morphological and biomechanical properties of rat th
Groups Dd (mm) Ds (mm) Ps (mmHg)
Control 1.58 ± 0.14 1.86 ± 0.22 82.67 ± 19.472
Diabetic 1.86 ± 0.18** 2.18 ± 0.18** 97.37 ± 15.011
Valsartan 1.75 ± 0.18* 2.08 ± 0.17* 71.22 ± 19.642
Abbreviations: CC compliance coefficient, DC distensibility coefficient, Dd diastolic d
*P < 0.05 vs control; **P < 0.01 vs control; ΔP < 0.05 vs diabetic.
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those in controls.
Discussion
We examined whether hyperglycemia in diabetic rats
promotes the accumulation of ECM in the thoracic aorta
through an Ang II-TSP1-TGFβ1/Smads pathway and
whether valsartan, an ARB widely used in clinical prac-
tice, could reverse such arterial remodeling. Diabetic
aortas showed reduced distensibility and compliance,
with excess ECM deposition, as compared with controls.
Components in the TSP1-mediated TGFβ1/Smads sig-
naling pathway, including TSP1, TGFβ1, TGFβ type II
receptor (TβRII), Smad2 and Smad3, were accumulated
in diabetic vascular smooth muscle cytoplasm, and their
protein and mRNA levels were upregulated. All these
abnormalities were attenuated by valsartan. Thus, activa-
tion of a TSP1-mediated TGFβ1/Smads pathway plays an
important role in marcovascular remodeling in T2DM,
and valsartan may hold promise for blocking the pathway
and ameliorating vascular fibrosis in diabetes.
Vascular complications of T2DM, including cardiovas-
cular diseases, retinopathy and nephropathy, impose a
substantial socioeconomic burden on public health. Ap-
proximately 50% of patients with T2DM die prematurely
of a cardiovascular cause and 10% die of renal failure
[16]. Abnormal arterial remodeling, paralleled by accel-
erated atherosclerosis, is responsible for the elevated in-
cidence of ischemic complications in diabetes. This
process extends to blood vessels of various caliber and
leads to an excessive accumulation of ECM. At the
macrovascular level, these alterations bring about nar-
rowed lumen, increased stiffness and decreased vasomo-
tion [17]. In the present and previous studies [2], we
used a high-calorie diet and low-dose STZ injection to
establish an animal T2DM model with specific metabolic
characteristics and demonstrated structural and func-
tional remodeling in the thoracic aorta.
The molecular mechanisms of arterial remodeling are
not fully elucidated. Multifunctional cytokines seem to
play a crucial role. TSP1-dependent TGFβ activation is
involved in the development of cardiac fibrosis in rats
with diabetes and elevated Ang II level [18]. Our current
study showed that TSP1-mediated TGFβ1/Smads signal-
ing is intensively involved in macrovascular fibrosis in-
duced by hyperglycemia. In parallel to upregulated TSP1oracic aorta with diabetes or valsartan treatment
Pd (mmHg) DC (1/kPa) CC (mm2/kPa)
64.00 ± 20.993 0.18 ± 0.10 0.48 ± 0.21
* 71.50 ± 13.135 0.11 ± 0.05* 0.33 ± 0.17*
△ 54.89 ± 19.161△ 0.24 ± 0.14△ 0.53 ± 0.31△
iameter, Ds systolic diameter.
Figure 2 Masson’s staining of thoracic aortas. Control (A), diabetic (B) and valsartan (C) aortas showing extracellular matrix (green).
Figure 3 Immunohistochemistry of protein content of components in the TSP1-mediated TGFβ1/Smads signaling pathway in aortas.
Staining for TSP1, A-TGFβ1, L-TGFβ1, TβRII, and p-Smad2/3 in aortic medial layer of control, diabetic and valsartan aortas and quantification (bottom).
*P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: A-TGFβ1, active transforming growth factor β1; L-TGFβ1, latent transforming growth factor β1;
p-Smad2/3, phosphorylated Smad2/3; TβRII, TGFβ type II receptor; TSP1, thrombospondin 1.
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Figure 4 RT-PCR analysis of mRNA level of components in the TSP1-mediated TGF β1/Smads signaling pathway in aortas. *P < 0.05.
Abbreviations: TGFβ1, transforming growth factor β1; TβRII, TGFβ type II receptor; TSP1, thrombospondin 1.
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TβRII, and p-Smad2/3 was upregulated, as was cellular
staining, which indicates TGFβ1 signaling activity. TSP1
is an extracellular calcium-binding multifunctional protein
first discovered in activated platelets. It is also secreted by
endothelial cells and smooth muscle cells. TSP1 triggers
the activation but not expression of TGFβ1 by interacting
with the LAP of latent TGFβ1 [19]. To initiate its cellular
action, TGFβ1 binds to TβRII and TβRI in sequence. After
activation, TβRI recruits and phosphorylates the ligand-
specific receptor-activated Smads (R-Smads), Smad2 and
Smad3, which then form heterometric complexes with a
co-Smad, Smad4, for subsequent nuclear signaling. Smad7
is an inhibitory Smad (I-Smad) and inactivates transcrip-
tion by binding with R-Smads or a co-Smad [20,21].
TGFβ1/Smads signaling modulates ECM by stimulating
fibrillar collagen genes and inhibiting matrix metallopro-
teinase genes [6]. Consistent with findings from rats with
diabetic cardiomyopathy [12,18], we observed a significant
increase in ECM content with activation of TGFβ1/Smads
signaling.
Under high glucose, Ang II production is elevated, with
disproportionate matrix deposition [22], which is related
to a mechanism dependent on protein kinase C (PKC) [8].
Although we did not determine Ang II level, the increased
TSP1-mediated TGFβ1/Smads signaling in diabetic aortas
was inhibited by an ARB, valsartan, and the pathological
features and biomechanical dysfunction of the diabetic
thoracic aorta were substantially improved.These results suggest an important role of RAS activa-
tion in diabetic fibrosis. Early experiments revealed that
glucose itself stimulates enhanced TSP1 transcription in
the aorta and carotid arteries [23], whereas in mesangial
cells, glucose stimulates TSP1 expression and TGFβ ac-
tivity through nuclear protein USF2 via PKC, p38
mitogen-activated protein kinase (p38 MAPK) and
extracellular signal-regulated kinase (ERK) pathways
[24]. In a hyperglycemic environment, Ang II stimulates
TSP1 upregulation and promotes subsequent activation
of TGFβ1. This process is facilitated by the canonical
Ang II subtype 1 receptor (AT1R) through p38 MAPK
and c-Jun NH2-terminal kinase (c-JNK) but not ERK1/2
[25]. Evidence from our current study and other reports
[13,18] suggests that the synergistic effects of glucose
and Ang II contribute to increased TSP1 expression and
consequent TGFβ1 activation.
The findings in this study that unfavorable morpho-
logical and functional alterations in diabetic aortas may
be partially reversed by inhibiting the detrimental effects
of Ang II are important for clinical practice. It provides
new insight into the mechanisms accounting for the vas-
cular benefits of interventions that block RAS overacti-
vation in diabetes. Recent clinical trials demonstrated
that stringent control of glycemia decreased the rate of
microvascular outcomes [26] but did not reduce major
cardiovascular events as compared with standard therapy
in high-risk patients with T2DM [27]. In addition, tight
control of systolic blood pressure was not associated with
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control treatment [28,29]. However, treatment with an
RAS antagonist-based regimen, including an Ang II con-
verting enzyme (ACE) inhibitor or ARB, prevented more
cardiovascular events than did other regimens in diabetic
patients with or without hypertension [30,31]. Although
numerous therapeutic strategies being developed target
the TGFβ1/Smads signaling pathway for treating fibrosis,
only a few studies have been performed in humans
[32,33]. Given the concern about unpredictable side ef-
fects of novel therapies, a practical approach for TGFβ1
antagonism is to extend the usefulness of available phar-
maceuticals. Tranilast, a membrane-stabilizing agent of
mast cells used for treating bronchial asthma, suppresses
collagen synthesis in early and advanced diabetic nephrop-
athy by interfering with the actions of TGFβ1 [34,35].
Similarly, as a type of competent antihypertensive agents
with favorable tolerability and safety, RAS inhibitors are
promising for combating diabetic fibrosis.
Conclusion
TSP1-mediated TGFβ1/Smads signaling is activated and
contributes to the redundant accumulation of ECM in-
duced by hyperglycemia in the rat diabetic thoracic
aorta. Blocking the RAS inhibits the expression of sig-
naling components and ameliorates the morphological
and biomechanical features of large arteries with diabetes,
which suggests an involvement of Ang II. Targeting the
Ang II-TSP1-TGFβ1/Smads signaling pathway is a feasible
therapeutic option to correct the aberrant macrovascular
remodeling in diabetes.
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